Hoffmann-La Roche $RO.SW
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS152
PHASE 3 / 2-392
RECRUITING61
READOUTS ≤12 MONTHS36
READOUT SLIPPED >6 MO48%
Delay Index: of 117 active trials registered more than a year ago, 56 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.1 months). See all sponsors →
Open Hoffmann-La Roche on the live radar map → 📅 $RO.SW readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| PASADENA NCT03100149 |
P2 | Active, not recruiting | Parkinson's Disease | 316 | 2019-11-27 (+4 mo) |
| OpRegen NCT02286089 |
P1/2 | Active, not recruiting | Age-Related Macular Degeneration | 24 | 2021-12-31 (+65 mo) |
| COMMODORE 3 NCT04654468 |
P3 | Active, not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 51 | 2022-02-10 (-10 mo) |
| Giredestrant NCT04576455 |
P2 | Active, not recruiting | Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | 303 | 2022-02-18 |
| COMMODORE 2 NCT04434092 |
P3 | Active, not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 210 | 2022-11-16 (+6 mo) |
| Rainbowfish NCT03779334 |
P2 | Active, not recruiting | Muscular Atrophy, Spinal | 26 | 2023-02-20 (+24 mo) |
| FENopta NCT05119569 |
P2 | Active, not recruiting | Relapsing Multiple Sclerosis | 109 | 2023-03-29 (+4 mo) |
| HAVEN 7 NCT04431726 |
P3 | Active, not recruiting | Severe Hemophilia A | 55 | 2023-05-22 (+5 mo) |
| Alectnib NCT03456076 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 257 | 2023-06-26 |
| INAVO120 NCT04191499 |
P2/3 | Active, not recruiting | Breast Cancer | 325 | 2023-09-29 (-25 mo) |
| Ocrelizumab NCT04075266 |
P2 | Active, not recruiting | Multiple Sclerosis | 23 | 2023-10-05 (+28 mo) |
| Radiotherapy NCT05009069 |
P2 | Active, not recruiting | Rectal Neoplasms; Rectal Cancer | 58 | 2023-11-21 (+5 mo) |
| Mosunetuzumab (IV) NCT03671018 |
P1/2 | Active, not recruiting | B-cell Non-Hodgkin Lymphoma | 422 | 2024-01-30 |
| IMforte NCT05091567 |
P3 | Active, not recruiting | Small-Cell Lung Cancer | 660 | 2024-07-29 (-7 mo) |
| REGENCY NCT04221477 |
P3 | Active, not recruiting | Lupus Nephritis | 271 | 2024-08-15 (+10 mo) |
| PADOVA NCT04777331 |
P2 | Active, not recruiting | Parkinsons Disease | 586 | 2024-09-11 (+10 mo) |
| Glofitamab NCT04980222 |
P2 | Active, not recruiting | Lymphoma | 46 | 2024-10-24 (-2 mo) |
| MUSETTE NCT04544436 |
P3 | Active, not recruiting | Multiple Sclerosis | 864 | 2024-12-19 (-4 mo) |
| O'HAND NCT04035005 |
P3 | Active, not recruiting | Multiple Sclerosis, Primary Progressive | 1013 | 2025-01-15 (-2 mo) |
| SUNMO NCT05171647 |
P3 | Active, not recruiting | Non-Hodgkin Lymphoma | 208 | 2025-02-17 (+17 mo) |
| SKYSCRAPER-14 NCT05904886 |
P3 | Active, not recruiting | Hepatocellular Carcinoma | 687 | 2025-05-08 (-16 mo) |
| Operetta 2 NCT05123703 |
P3 | Active, not recruiting | Relapsing-remitting Multiple Sclerosis | 188 | 2025-06-09 |
| GAVOTTE NCT04548999 |
P3 | Active, not recruiting | Multiple Sclerosis | 769 | 2025-06-30 (+4 mo) |
| COMMUTE-p NCT04958265 |
P3 | Active, not recruiting | Atypical Hemolytic Uremic Syndrome | 41 | 2025-07-04 (-5 mo) |
| Giredestrant NCT04961996 |
P3 | Active, not recruiting | Early Breast Cancer | 4170 | 2025-08-08 (-4 mo) |
| FENhance 2 NCT04586023 |
P3 | Active, not recruiting | Relapsing Multiple Sclerosis | 751 | 2025-09-05 (+12 mo) |
| ALLEGORY NCT04963296 |
P3 | Active, not recruiting | Systemic Lupus Erythematosus | 303 | 2025-09-15 (-2 mo) |
| FENtrepid NCT04544449 |
P3 | Active, not recruiting | Multiple Sclerosis, Primary Progressive | 985 | 2025-09-17 (+4 mo) |
| COMMUTE-a NCT04861259 |
P3 | Active, not recruiting | Atypical Hemolytic Uremic Syndrome | 83 | 2025-10-09 (+19 mo) |
| Meteoroid NCT05271409 |
P3 | Active, not recruiting | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | 139 | 2025-11-20 (+1 mo) |
| MAJESTY NCT04629248 |
P3 | Active, not recruiting | Primary Membranous Nephropathy | 142 | 2025-12-22 (+11 mo) |
| Atezolizumab NCT05047250 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 60 | 2025-12-30 (+21 mo) |
| FENhance NCT04586010 |
P3 | Active, not recruiting | Relapsing Multiple Sclerosis | 746 | 2026-01-27 (+16 mo) |
| Giredestrant NCT04546009 |
P3 | Active, not recruiting | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | 992 | 2026-01-30 (+21 mo) |
| ENVOL NCT06128564 |
P2 | Active, not recruiting | Duchenne Muscular Dystrophy | 13 | 2026-03-04 (-81 mo) |
| Tominersen NCT05686551 |
P2 | Active, not recruiting | Huntington Disease | 301 | 2026-05-14 (+16 mo) |
| Krascendo 1 NCT06497556 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer | 338 | 2026-05-19 (-2 mo) |
| Celestimo NCT04712097 |
P3 | Active, not recruiting | Relapsed or Refractory Follicular Lymphoma | 478 | 2026-06-03 (-35 mo) |
| Afimkibart NCT06863961 |
P2 | Active, not recruiting | Atopic Dermatitis | 162 | 2026-07-22 (+2 mo) |
| GYMINDA NCT06965413 |
P2 | Active, not recruiting | Obesity; Overweight | 285 | 2026-09-03 (-2 mo) |
| PORTAMENTO NCT07074886 |
P2 | Active, not recruiting | Multiple Sclerosis | 193 | 2026-09-17 (-4 mo) |
| Entrectinib NCT04603807 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 217 | 2026-09-30 (-4 mo) |
| IMbrave251 NCT04770896 |
P3 | Active, not recruiting | Unresectable Hepatocellular Carcinoma | 557 | 2026-10-14 (+25 mo) |
| CONSONANCE NCT03523858 |
P3 | Active, not recruiting | Progressive Multiple Sclerosis (PMS) | 927 | 2026-10-22 (+37 mo) |
| Ametrine-2 NCT06588855 |
P3 | Active, not recruiting | Moderately to Severely Active Ulcerative Colitis | 350 | 2026-10-29 (-8 mo) |
| INAVO121 NCT05646862 |
P3 | Recruiting | Breast Cancer | 420 | 2026-11-13 (-19 mo) |
| SHIELD DMD NCT06450639 |
P2 | Active, not recruiting | Duchenne Muscular Dystrophy | 30 | 2026-11-18 (+5 mo) |
| RO7269162 NCT06402838 |
P2 | Active, not recruiting | Alzheimer's Disease | 256 | 2026-11-19 (-6 mo) |
| Atezolizumab NCT03148418 |
P3 | Active, not recruiting | Cancer | 382 | 2026-11-30 (-8 mo) |
| Cielo NCT05503264 |
P3 | Active, not recruiting | NMDAR Autoimmune Encephalitis; LGI1 Autoimmune Encephalitis | 122 | 2026-12-16 (+18 mo) |
| Englumafusp alfa NCT04077723 |
P1/2 | Active, not recruiting | Lymphoma, Non-Hodgkin | 498 | 2026-12-28 (+48 mo) |
| Atezolizumab NCT05645692 |
P2 | Active, not recruiting | Urothelial Cancer | 204 | 2026-12-31 |
| TAHOE NCT05910528 |
P2 | Active, not recruiting | Crohns Disease | 21 | 2026-12-31 (+25 mo) |
| HORIZON 1 NCT05170204 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 68 | 2027-01-19 (-29 mo) |
| Ametrine-1 NCT06589986 |
P3 | Active, not recruiting | Moderately to Severely Active Ulcerative Colitis | 400 | 2027-01-30 (-5 mo) |
| Ranibizumab NCT04657289 |
P3 | Active, not recruiting | Neovascular Age-related Macular Degeneration (nAMD) | 451 | 2027-02-04 (+40 mo) |
| CAMMA 2 NCT05535244 |
P1/2 | Active, not recruiting | Multiple Myeloma | 90 | 2027-02-26 (+3 mo) |
| Pertuzumab NCT02320435 |
P3 | Active, not recruiting | Solid Tumors | 154 | 2027-03-28 (+27 mo) |
| Astefania NCT04873362 |
P3 | Active, not recruiting | Breast Cancer | 1188 | 2027-03-31 (+15 mo) |
| SAkuraSun NCT05199688 |
P3 | Recruiting | Neuromyelitis Optica Spectrum Disorder; NMOSD | 8 | 2027-03-31 (+32 mo) |
| Afimkibart NCT07137598 |
P2 | Recruiting | Rheumatoid Arthritis | 160 | 2027-04-17 (-3 mo) |
| COMMODORE 1 NCT04432584 |
P3 | Active, not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 190 | 2027-04-18 (+69 mo) |
| Pearlstone NCT07827599 |
P3 | Recruiting | Influenza, Human; Respiratory Tract Infections | 325 | 2027-04-30 |
| INAVO122 NCT05894239 |
P3 | Recruiting | Metastatic Breast Cancer | 230 | 2027-05-03 (-18 mo) |
| Pebblestone NCT06094010 |
P3 | Recruiting | Influenza | 1100 | 2027-05-11 |
| FENerations1 NCT07161258 |
P2 | Recruiting | Relapsing Multiple Sclerosis | 12 | 2027-06-08 |
| HUTONG NCT05562947 |
P3 | Active, not recruiting | Neovascular Age-related Macular Degeneration; nAMD | 68 | 2027-06-30 (+4 mo) |
| B-FAST NCT03178552 |
P2/3 | Active, not recruiting | Non-Small Cell Lung Cancer | 1000 | 2027-06-30 (+88 mo) |
| STARTRK-NG NCT02650401 |
P1/2 | Active, not recruiting | Solid Tumors; CNS Tumors | 69 | 2027-06-30 (+106 mo) |
| Atezolizumab NCT05112965 |
P3 | Active, not recruiting | Neoplasms | 49 | 2027-06-30 (+19 mo) |
| RO7247669 NCT04140500 |
P1/2 | Active, not recruiting | Solid Tumors; Metastatic Melanoma | 170 | 2027-06-30 (+61 mo) |
| Astegolimab NCT05878769 |
P3 | Active, not recruiting | Chronic Obstructive Pulmonary Disease | 2000 | 2027-06-30 |
| Pagoda NCT04108156 |
P3 | Active, not recruiting | Diabetic Macular Edema | 672 | 2027-07-20 (+69 mo) |
| MORPHEUS-LIVER NCT04524871 |
P1/2 | Active, not recruiting | Advanced Liver Cancers | 518 | 2027-07-30 (+69 mo) |
| Inavolisib NCT07054190 |
P2 | Recruiting | Breast Cancer | 120 | 2027-07-31 (+5 mo) |
| RO7126209 NCT04639050 |
P1/2 | Active, not recruiting | Alzheimers Disease | 241 | 2027-07-31 (+34 mo) |
| ZN-A-1041 NCT05593094 |
P1/2 | Active, not recruiting | Advanced Solid Tumors; HER2-positive Breast Cancer | 210 | 2027-08-31 (+53 mo) |
| GLOBRYTE NCT06084936 |
P3 | Recruiting | Lymphoma | 182 | 2027-08-31 (+19 mo) |
| ZEBRHA 1 NCT07416526 |
P3 | Recruiting | Hemophilia A | 138 | 2027-09-23 |
| Glofitamab NCT06047080 |
P3 | Active, not recruiting | Large B-Cell Lymphoma | 1130 | 2027-10-01 (+16 mo) |
| WILL-EMI NCT06998524 |
P3 | Recruiting | Von Willebrand Disease, Type 3 | 75 | 2027-10-06 (-2 mo) |
| IMCODE004 NCT06534983 |
P2 | Active, not recruiting | Muscle-invasive Urothelial Carcinoma | 62 | 2027-11-10 (-12 mo) |
| ZYNERGY NCT07589686 |
P2 | Not yet recruiting | Obesity or Overweight | 486 | 2027-11-12 |
| OLERO NCT05269004 |
P3 | Active, not recruiting | Multiple Sclerosis | 1300 | 2027-12-31 (+24 mo) |
| Tifeglipron NCT07112872 |
P2 | Recruiting | Type 2 Diabetes Mellitus | 330 | 2028-02-05 (+12 mo) |
| TRONTIER 2 NCT07170150 |
P3 | Active, not recruiting | Alzheimers Disease | 1060 | 2028-02-16 (-5 mo) |
| TRONTIER 1 NCT07169578 |
P3 | Active, not recruiting | Alzheimers Disease | 1101 | 2028-02-16 (-5 mo) |
| Enicepatide NCT07670416 |
P3 | Recruiting | Obesity; Overweight | 300 | 2028-02-24 |
| BOUQUET NCT04931342 |
P2 | Active, not recruiting | Ovarian Cancer | 176 | 2028-02-28 (+42 mo) |
| ZEBRHA 2 NCT07416604 |
P3 | Recruiting | Hemophilia A | 360 | 2028-02-29 |
| InavoPC NCT07287150 |
P2 | Recruiting | Metastatic Castration-Resistant Prostate Cancer | 100 | 2028-03-31 |
| Obinutuzumab NCT04408638 |
P3 | Active, not recruiting | Diffuse Large B-cell Lymphoma | 270 | 2028-03-31 (+73 mo) |
| Giredestrant NCT06065748 |
P3 | Active, not recruiting | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | 1050 | 2028-04-20 (+21 mo) |
| IMAGINATION NCT05797610 |
P3 | Active, not recruiting | Primary IgA Nephropathy | 459 | 2028-05-25 (+20 mo) |
| Mintaka NCT07282574 |
P2 | Recruiting | Progressive Multiple Sclerosis | 360 | 2028-05-30 |
| AMETRINE-SC NCT07846683 |
P3 | Recruiting | Moderately to Severely Active Ulcerative Colitis | 350 | 2028-05-31 |
| Phesgo NCT05296798 |
P3 | Active, not recruiting | Locally Advanced or Metastatic Breast Cancer | 922 | 2028-06-15 (+21 mo) |
| POSTERITY NCT05039619 |
P2 | Recruiting | Lupus Nephritis | 40 | 2028-06-15 (+39 mo) |
| Pegozafermin NCT06419374 |
P3 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | 1800 | 2028-06-30 (-21 mo) |
| IMbrella B NCT03768063 |
P3 | Active, not recruiting | Cancer | 1000 | 2028-07-05 (-6 mo) |
| Enith1 NCT07351045 |
P3 | Recruiting | Obesity or Overweight | 2000 | 2028-07-24 |
| PLYCOM NCT05583617 |
P1/2 | Recruiting | Multiple Myeloma | 200 | 2028-07-31 (+58 mo) |
| Enith2 NCT07351058 |
P3 | Recruiting | Obesity or Overweight; Type 2 Diabetes Mellitus | 1600 | 2028-08-07 |
| SOLUNA NCT07598396 |
P2 | Recruiting | Lupus; Systemic Lupus Erythematosus | 30 | 2028-08-11 |
| ZEBRHA 3 NCT07838194 |
P3 | Recruiting | Hemophilia A | 50 | 2028-09-30 |
| RO7830698 NCT07822334 |
P1/2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD); Healthy Participants | 104 | 2028-10-11 |
| ZUPREME-4 NCT07843485 |
P3 | Recruiting | Obesity or Overweight; Type 2 Diabetes | 600 | 2028-10-20 |
| optINAVO NCT07368998 |
P2 | Recruiting | Breast Cancer | 80 | 2028-10-31 |
| CEVOLUTION NCT07555938 |
P3 | Recruiting | Multiple Myeloma | 380 | 2028-10-31 |
| Sightspire NCT06847542 |
P3 | Recruiting | Neovascular Age-related Macular Degeneration | 250 | 2028-11-15 (+4 mo) |
| Krascendo 2 NCT06793215 |
P3 | Recruiting | Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer | 600 | 2028-11-30 (+7 mo) |
| kalitERA NCT07827573 |
P3 | Recruiting | Early Breast Cancer; Estrogen Receptor-Positive Breast Cancer | 1500 | 2028-11-30 |
| TARBELA-PD NCT07781644 |
P2 | Recruiting | Parkinson's Disease | 474 | 2028-12-15 |
| Inavolisib NCT07405801 |
P2 | Recruiting | Breast Cancer | 80 | 2028-12-19 |
| ZUPREME-3 NCT07843498 |
P3 | Recruiting | Obesity or Overweight | 3900 | 2028-12-21 |
| SIBERITE-1 NCT06819878 |
P3 | Recruiting | Moderately to Severely Active Crohns Disease | 600 | 2028-12-31 |
| SIBERITE-2 NCT06819891 |
P3 | Recruiting | Moderately to Severely Active Crohns Disease | 425 | 2028-12-31 |
| Pegozafermin NCT06318169 |
P3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis | 1350 | 2029-02 (+26 mo) |
| Atezolizumab NCT04712643 |
P3 | Active, not recruiting | Hepatocellular Carcinoma | 342 | 2029-02-01 (+47 mo) |
| Glofitamab NCT03075696 |
P1/2 | Active, not recruiting | Non-Hodgkin's Lymphoma | 940 | 2029-03-30 |
| ENI-SPIRE-2 NCT07889648 |
P3 | Not yet recruiting | Type 2 Diabetes Mellitus | 948 | 2029-04-02 |
| Cevostamab NCT07825064 |
P2 | Recruiting | Multiple Myeloma | 45 | 2029-04-13 |
| BREnnA NCT07413939 |
P2/3 | Recruiting | HER2-positive Breast Cancer | 650 | 2029-05-01 |
| Giredestrant NCT04802759 |
P1/2 | Recruiting | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | 316 | 2029-05-30 (+31 mo) |
| Inavolisib NCT07748208 |
P2 | Recruiting | Breast Cancer; Diabetes Type II | 40 | 2029-06-15 |
| PARAISO NCT07174310 |
P3 | Recruiting | Parkinson's Disease | 900 | 2029-06-30 |
| Obinutuzumab NCT06806033 |
P2 | Recruiting | Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma | 130 | 2029-07-31 (+28 mo) |
| Operetta III NCT07503340 |
P2 | Not yet recruiting | Relapsing-remitting Multiple Sclerosis | 25 | 2029-08-31 |
| TARBELA-AD NCT07781657 |
P2 | Recruiting | Alzheimer's Disease | 450 | 2029-11-01 |
| iMATRIX GLO NCT05533775 |
P1/2 | Recruiting | Mature B-Cell Non-Hodgkin Lymphoma | 65 | 2029-11-30 (+26 mo) |
| Fenebrutinib NCT07937852 |
P3 | Not yet recruiting | Multiple Sclerosis | 1800 | 2029-11-30 |
| OleroMAX NCT06675955 |
P3 | Recruiting | Multiple Sclerosis | 500 | 2029-12-31 |
| Portal NCT03683251 |
P3 | Recruiting | Neovascular Age-Related Macular Degeneration | 1000 | 2029-12-31 (+90 mo) |
| AMETRINE-PEDS NCT07158242 |
P3 | Recruiting | Moderately to Severely Active Ulcerative Colitis | 100 | 2030-03-31 |
| SIBERITE-PEDS NCT07298421 |
P3 | Recruiting | Moderately to Severely Active Crohns Disease | 100 | 2030-05-31 |
| ZUPREME-5 NCT07843472 |
P3 | Recruiting | Obesity or Overweight; Cardiovascular Disease | 2500 | 2030-07-28 |
| Mosunetuzumab (IV) NCT04246086 |
P1/2 | Active, not recruiting | Follicular Lymphoma | 237 | 2030-09-06 (+98 mo) |
| Morpheus-panBC NCT03424005 |
P1/2 | Recruiting | Metastatic Breast Cancer | 1132 | 2030-09-30 (+110 mo) |
| Enith-MACE NCT07918846 |
P3 | Not yet recruiting | Overweight; Obesity | 8200 | 2031-03-20 |
| KRAScendo 170 NCT05789082 |
P1/2 | Recruiting | Non-Small Cell Lung Cancer | 320 | 2032-01-29 (+76 mo) |
| KRASCENDO 3 NCT07541170 |
P3 | Recruiting | Non-small Cell Lung Cancer | 400 | 2032-01-31 |
| INAVO123 NCT06790693 |
P3 | Recruiting | Breast Cancer | 450 | 2032-01-31 (+48 mo) |
| Alectinib NCT04774718 |
P1/2 | Active, not recruiting | ALK Fusion-positive Solid or CNS Tumors | 42 | 2032-02-28 (+56 mo) |
| SPK-8011QQ NCT07226206 |
P1/2 | Recruiting | Hemophilia A | 5 | 2032-04-30 (+15 mo) |
| PrevenTRON NCT07717411 |
P3 | Recruiting | Alzheimer's Disease | 1600 | 2032-07-30 |
| Entrectinib NCT04589845 |
P2 | Active, not recruiting | Solid Tumors | 920 | 2032-09-25 |
| Velarite-LTE NCT07223697 |
P2 | Active, not recruiting | Atopic Dermatitis | 120 | 2033-03-01 |
| UmbrellaMAX NCT05862285 |
P3 | Recruiting | Cancer | 200 | 2033-03-01 (-2 mo) |
| dRAvite-LTE NCT07620392 |
P2 | Recruiting | Rheumatoid Arthritis | 120 | 2033-07-08 |
| NXT007 NCT05987449 |
P1/2 | Recruiting | Hemophilia A | 60 | 2033-12-11 (+18 mo) |
| SPK-10001 NCT06826612 |
P1/2 | Recruiting | Huntington Disease | 53 | 2035-01-12 |
| TRAVELLER NCT07177352 |
P3 | Recruiting | Alzheimers Disease | 80000 | 2035-07-31 |